Cencora Expands Credit Facilities to Finance OneOncology Deal

Cencora ( (COR) ) just unveiled an update.

On January 12, 2026, Cencora, Inc. amended its existing revolving credit agreement, increasing total commitments by $1.0 billion to $5.5 billion, enhancing its overall liquidity profile. On the same date, the company secured a new senior unsecured multi-year term loan facility totaling $1.5 billion in two tranches and a separate $3.0 billion 364-day senior unsecured term loan facility, both primarily to finance its proposed acquisition of the remaining majority equity interests in OneOncology, refinance OneOncology’s existing debt and cover related fees and expenses, with the loans bearing interest at SOFR- or base-rate benchmarks plus ratings-based margins and subject to leverage and other customary covenants and events of default. Together, these new term facilities fully displaced the previously arranged $4.5 billion bridge financing commitment, reducing it to zero, and further embedded major relationship banks such as JPMorgan Chase, Citibank, Bank of America, Wells Fargo, BNP Paribas, Société Générale and MUFG in Cencora’s capital structure through roles as lenders, advisors, underwriters and securitization counterparties, underscoring the scale and importance of the OneOncology transaction for the company’s financing strategy and banking relationships.

The most recent analyst rating on (COR) stock is a Buy with a $415.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.

Spark’s Take on COR Stock

According to Spark, TipRanks’ AI Analyst, COR is a Neutral.

Cencora’s strong financial performance and positive earnings call sentiment are major strengths, driving the score. However, high leverage, potential overvaluation, and technical indicators suggesting bearish momentum are notable risks.

To see Spark’s full report on COR stock, click here.

More about Cencora

Cencora, Inc. operates in the healthcare sector, focusing on pharmaceutical distribution and related services, including specialty healthcare solutions. The company works closely with healthcare providers and manufacturers, and has an active presence in capital markets and structured financing, as reflected in its use of revolving credit facilities, term loans and receivables securitization programs to support acquisitions and ongoing operations.

Average Trading Volume: 1,400,831

Technical Sentiment Signal: Buy

Current Market Cap: $67.88B

See more insights into COR stock on TipRanks’ Stock Analysis page.